Skip to main content

Drug Interactions between measles virus vaccine / rubella virus vaccine and siponimod

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

measles virus vaccine siponimod

Applies to: measles virus vaccine / rubella virus vaccine and siponimod

GENERALLY AVOID: The administration of live, attenuated viral or bacterial vaccines during siponimod therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Siponimod causes reversible sequestration of lymphocytes in lymphoid tissues. A dose-dependent reduction in peripheral lymphocyte count to 20% to 30% of baseline values has been observed, which may increase the risk of infections. Vaccination may also be less effective during and for up to one month after discontinuation of siponimod therapy.

MANAGEMENT: The use of live attenuated vaccines should be avoided during and for up to 4 weeks after siponimod treatment, and siponimod should be paused 1 week prior to and until 4 weeks after a planned vaccination. Patients without a healthcare professional confirmed history of varicella or without documentation of a full course of vaccination against varicella-zoster virus (VZV) should be tested for antibodies to VZV before initiating treatment with siponimod. For antibody-negative patients, a full course of vaccination with varicella vaccine is recommended prior to treatment with siponimod. In patients who have recently been vaccinated, siponimod therapy should be postponed for 4 weeks to allow the full effect of vaccination to occur. Administration of live attenuated vaccines in severely immunocompromised persons is generally considered a contraindication. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for further information.

References

  1. Cerner Multum, Inc. "Australian Product Information."
  2. (2019) "Product Information. Mayzent (siponimod)." Novartis Pharmaceuticals
  3. Advisory Committee on Immunization Practices: Centers for Disease Control and Prevention General Best Practice Guidelines for Immunization: Contraindications and Precautions: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html

Switch to consumer interaction data

Major

rubella virus vaccine siponimod

Applies to: measles virus vaccine / rubella virus vaccine and siponimod

GENERALLY AVOID: The administration of live, attenuated viral or bacterial vaccines during siponimod therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Siponimod causes reversible sequestration of lymphocytes in lymphoid tissues. A dose-dependent reduction in peripheral lymphocyte count to 20% to 30% of baseline values has been observed, which may increase the risk of infections. Vaccination may also be less effective during and for up to one month after discontinuation of siponimod therapy.

MANAGEMENT: The use of live attenuated vaccines should be avoided during and for up to 4 weeks after siponimod treatment, and siponimod should be paused 1 week prior to and until 4 weeks after a planned vaccination. Patients without a healthcare professional confirmed history of varicella or without documentation of a full course of vaccination against varicella-zoster virus (VZV) should be tested for antibodies to VZV before initiating treatment with siponimod. For antibody-negative patients, a full course of vaccination with varicella vaccine is recommended prior to treatment with siponimod. In patients who have recently been vaccinated, siponimod therapy should be postponed for 4 weeks to allow the full effect of vaccination to occur. Administration of live attenuated vaccines in severely immunocompromised persons is generally considered a contraindication. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for further information.

References

  1. Cerner Multum, Inc. "Australian Product Information."
  2. (2019) "Product Information. Mayzent (siponimod)." Novartis Pharmaceuticals
  3. Advisory Committee on Immunization Practices: Centers for Disease Control and Prevention General Best Practice Guidelines for Immunization: Contraindications and Precautions: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer